These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 23201855)

  • 21. Driving a decade of change: HIV/AIDS, patents and access to medicines for all.
    Hoen E'; Berger J; Calmy A; Moon S
    J Int AIDS Soc; 2011 Mar; 14():15. PubMed ID: 21439089
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TRIPS post-2005 and access to new antiretroviral treatments in southern countries: issues and challenges.
    Orsi F; D'Almeida C; Hasenclever L; Camara M; Tigre P; Coriat B
    AIDS; 2007 Oct; 21(15):1997-2003. PubMed ID: 17885289
    [No Abstract]   [Full Text] [Related]  

  • 23. A trade agreement's impact on access to generic drugs.
    Shaffer ER; Brenner JE
    Health Aff (Millwood); 2009; 28(5):w957-68. PubMed ID: 19706626
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does the political will exist to bring quality-assured and affordable drugs to low- and middle-income countries?
    Beck EJ; Mandalia S; DongmoNguimfack B; Pinheiro E; 't Hoen E; Boulet P; Stover J; Gupta A; Juneja S; Habiyambere V; Ghys P; Nunez C
    Glob Health Action; 2019; 12(1):1586317. PubMed ID: 30983547
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Public health-oriented intellectual property and trade policies in Africa and the regional mechanism under Trade-Related Aspects of Intellectual Property Rights amendment.
    Adekola TA
    Public Health; 2019 Aug; 173():1-4. PubMed ID: 31203136
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Evolution of the international intellectual property rights system: patent protection for the pharmaceutical industry and access to medicines].
    Chaves GC; Oliveira MA; Hasenclever L; de Melo LM
    Cad Saude Publica; 2007 Feb; 23(2):257-67. PubMed ID: 17221075
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Addressing legal and political barriers to global pharmaceutical access: options for remedying the impact of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and the imposition of TRIPS-plus standards.
    Cohen-Kohler JC; Forman L; Lipkus N
    Health Econ Policy Law; 2008 Jul; 3(Pt 3):229-56. PubMed ID: 18634618
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The new patent regime and disease priorities in India.
    Gupta I; Guin P; Trivedi M
    Glob Public Health; 2013; 8(1):37-54. PubMed ID: 22845021
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Access to generic antiretrovirals: inequality, intellectual property law, and international trade agreements.
    Castro A; Westerhaus M
    Cad Saude Publica; 2007; 23 Suppl 1():S85-96. PubMed ID: 17308722
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The right to health and medicines: the case of recent multilateral negotiations on public health, innovation and intellectual property.
    Velasquez G
    Dev World Bioeth; 2014 Aug; 14(2):67-74. PubMed ID: 24813066
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes to intellectual property policy in South Africa: putting a stop to evergreening?
    Hill JE
    Expert Opin Ther Pat; 2014 Aug; 24(8):839-43. PubMed ID: 24965317
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Access to essential medicines: a Hobbesian social contract approach.
    Ashcroft RE
    Dev World Bioeth; 2005 May; 5(2):121-41. PubMed ID: 15842722
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A method for understanding generic procurement of HIV medicines by developing countries with patent protection.
    Beall RF; Attaran A
    Soc Sci Med; 2017 Jul; 185():118-126. PubMed ID: 28578209
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Benchmarking progress in tackling the challenges of intellectual property, and access to medicines in developing countries.
    Musungu SF
    Bull World Health Organ; 2006 May; 84(5):366-70. PubMed ID: 16710545
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TRIPS, the Doha Declaration and increasing access to medicines: policy options for Ghana.
    Cohen JC; Gyansa-Lutterodt M; Torpey K; Esmail LC; Kurokawa G
    Global Health; 2005 Dec; 1():17. PubMed ID: 16336685
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TRIPS, the Doha declaration and paragraph 6 decision: what are the remaining steps for protecting access to medicines?
    Kerry VB; Lee K
    Global Health; 2007 May; 3():3. PubMed ID: 17524147
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cambodia's Imminent Graduation from Least Developed Country Status: What Will be the Impact of the TRIPS Agreement on Access to HIV and Hepatitis C Medicines in Cambodia?
    Tenni B; Lexchin J; Phin S; Gleeson D
    Int J Soc Determinants Health Health Serv; 2024 Jul; 54(3):295-308. PubMed ID: 38563076
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Africa, access, and patents: moving fast.
    James JS
    AIDS Treat News; 1999 Jul; (No 322):5-8. PubMed ID: 11366567
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Global trade and health: key linkages and future challenges.
    Bettcher DW; Yach D; Guindon GE
    Bull World Health Organ; 2000; 78(4):521-34. PubMed ID: 10885181
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trade agreements, intellectual property, and the role of the World Bank in improving access to medicines in developing countries.
    Rovira J
    Yale J Health Policy Law Ethics; 2004; 4(2):401-13. PubMed ID: 15536921
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.